MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma

Despite the improvement in clinical outcome with 13-cis-retinoic acid (13-cisRA) + anti-GD2 antibody + cytokine immunotherapy given in first response ~40% of high-risk neuroblastoma patients die of recurrent disease. MYCN genomic amplification is a biomarker of aggressive tumors in the childhood can...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Sung-Jen, Nguyen, Thinh H., Yang, In-Hyoung, Mook, Dustin G., Makena, Monish Ram, Verlekar, Dattesh, Hindle, Ashly, Martinez, Gloria M., Yang, Shengping, Shimada, Hiroyuki, Reynolds, C. Patrick, Kang, Min H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224192/
https://www.ncbi.nlm.nih.gov/pubmed/32409685
http://dx.doi.org/10.1038/s41419-020-2563-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224192/
https://www.ncbi.nlm.nih.gov/pubmed/32409685
http://dx.doi.org/10.1038/s41419-020-2563-4

Ejemplares similares